Cis-Diamminedichloroplatinum Ii
Malignant Pleural Mesothelioma
Explore 35 assets in Malignant Pleural Mesothelioma →Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06535607CT.gov Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04491942CT.gov Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | — | Active Not Recruiting | — | — | — |
NCT03920839CT.gov INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | — | Withdrawn | — | — | — |
NCT02535312CT.gov Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | — | Active Not Recruiting | — | — | — |
NCT02347917CT.gov A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | — | Completed | — | — | — |
NCT00700336CT.gov Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pleural Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | AstraZeneca | P2 | BB · 71 |
| Carboplatin | AstraZeneca | P2 | BB |
| Pembrolizumab | NuCana plc | P2 | B |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P2 | B |
| Atezolizumab | Swiss Cancer Institute | P2 | B |
| Decitabine | National Cancer Institute (NCI) | P1/2 | CCC |
| 68Ga-NOTA-AE105 | Rigshospitalet, Denmark | P2 | CCC |
| Tislelizumab | Translational Research in Oncology | P2 | CCC |
| Regorafenib | Translational Research in Oncology | P2 | CCC |
+42 more in the Malignant Pleural Mesothelioma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Malignant Pleural Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-malignant-pleural-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →